Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Alector ( (ALEC) ) has provided an announcement.
Alector, Inc. is implementing a 17% workforce reduction to align with strategic priorities after its INVOKE-2 trial of AL002 in early Alzheimer’s disease did not meet primary endpoints. Despite these setbacks, Alector remains committed to advancing its drug candidates for neurodegenerative diseases and expects its cash reserves to fund operations through 2026. The company continues to develop its Alector Brain Carrier platform and other promising therapies, aiming to improve patient outcomes with innovative treatments.
Learn more about ALEC stock on TipRanks’ Stock Analysis page.
